News
Cassava Sciences announces initiation of simufilam in patients with Alzheimer’s disease in a phase III cognition maintenance study.
Cassava Sciences, Inc.has announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam is a drug candidate that seeks to reduce neurodegeneration and neuroinflammation.
Cassava Sciences, Inc.has announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam is a drug candidate that seeks to reduce neurodegeneration and neuroinflammation. Cassava Sciences believes the ability to impact more than one aspect of Alzheimer’s disease represents a new and crucial approach to treatment.
In addition to initiating the CMS and conducting an on-going open-label study, Cassava Sciences’ strategic focus for 2021 is to advance simufilam in a Phase III program in Alzheimer’s disease, to complete clinical readiness activities in support of the Phase III program, and to continue to lead the Company to deliver the full potential of its product portfolio.
About the Cognition Maintenance Study (CMS) : The CMS is a double-blind, multi-center, randomized, placebo-controlled clinical study in subjects with mild-to-moderate Alzheimer’s disease. Upon enrolling into the CMS, all study participants will already have completed at least one year of open-label treatment with simufilam. CMS participants will be randomized (1:1) to simufilam 100 mg tablets twice-daily or matching placebo for six months. The CMS design includes measures of safety and a single primary endpoint of cognition, measured on ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale). Target enrollment is up to 100 subjects across multiple study sites in the U.S. and Canada.
Condition: Alzheimers
Type: drug